Dr. Swayampakula Ramakanth is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. Dr. Ramakanth’s research covers companies operating in oncology, wound health, medical devices, spine health and animal health. Dr. Ramakanth possesses over ten years of experience as a Life Sciences Equity Analyst as well as seven years of biotechnology industry experience. Prior to joining H.C. Wainwright, Dr. Ramakanth worked as a Junior Analyst at both Jefferies and Merrill Lynch covering large cap pharmaceuticals.
Analyst: Edward White
AnalystEdward White is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on both the biotechnology and the specialty pharmaceutical sectors. Mr. White’s expertise covers companies operating in the oncology, immune-oncology, infectious disease, and gastrointestinal sectors. Prior to working at H.C. Wainwright, Mr. White has worked as a Wall Street Healthcare Analyst, on both the buy-side and the sell-side, since 1996. Mr. White’s previous sell-side experience includes working for Fahnestock & Company (now Oppenheimer), Gerard, Klauer, Mattison & Company (now BMO Capital Markets), Deutsche Bank Securities, and a couple of boutique firms.
Analyst: Doug Tsao
Analyst
Doug Tsao is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on Biopharmaceuticals and Specialty Pharmaceuticals. Specific therapeutics areas include Endocrinology, Metabolic disease, Dermatology, and CNS in addition to other areas. Prior to joining H.C. Wainwright, Mr. Tsao was a senior equity research analyst at Barclays covering U.S. Specialty Pharmaceutical companies as well as small and midcap medical device companies.
Analyst: Raghuram Selvaraju Ph.D.
Analyst
Dr. Raghuram Selvaraju is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. Dr. Selvaraju possesses over a decade’s worth of experience in Healthcare Equity Research. Dr. Selvaraju was ranked by both the StarMine for his earnings accuracy and by The Wall Street journal’s annual Best on the Street Analyst for his stock-picking performance. In addition, Dr. Selvaraju has appeared numerous times on Bloomberg, CNBC, Business News Network and BTV where he discussed drug development trends, healthcare reform policy, and pharma and biotech M&A.
Analyst: Joseph Pantginis, Ph.D.
Analyst
Dr. Joseph Pantginis is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. Dr. Pantginis conducted more than seventeen years of healthcare equity research. Prior to joining H.C. Wainwright, Dr. Pantginis worked as a Senior Research Analyst and Head of Biotechnology Research at ROTH Capital Partners. Dr. Pantginis also held senior positions at Merriman, Canaccord Adams, Commerce Capital Markets, JBHanauer and Ladenburg. Prior to his equity research career, Dr. Pantginis worked at Regeneron Pharmaceuticals, where he founded the Retroviral Core Facility.
Analyst: Oren G. Livnat
Analyst
Oren G. Livnat is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the specialty pharmaceutical industry. Mr. Livnat conducted more than twelve years of research on both the sell-side and the buy-side. Prior to joining H.C. Wainwright, Mr. Livnat worked as a Senior Analyst covering specialty and generic pharma at Iguana Healthcare Partners, a dedicated healthcare long/short hedge fund. Mr. Livnat began his career as an Associate at Natixis Bleichroeder and successively worked as a Senior Analyst at JMP Securities covering both commercial and development-stage companies.
Analyst: Heiko Ihle
Analyst
Heiko Ihle is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on companies in the Metals and Mining industry. Prior to joining H.C. Wainwright, Mr. Ihle worked as a Senior Research Analyst at Euro Pacific Capital where his research was also focused on the Mining industry. Prior to that, Mr. Ihle worked at Gabelli & Company covering both the Industrials and E&C industries. Mr. Ihle also completed summer internships with Deutsche Bank on the foreign exchange trading desk and on fixed income sales, in New York and Germany, respectively.
Analyst: Andrew Fein
Analyst
Andrew Fein is a Managing Director of Equity Research at H.C. Wainwright. Mr. Fein conducted more than twelve years of biotechnology equity research. Prior to joining H.C. Wainwright, Mr. Fein worked as the Head of the Healthcare Research effort at Chardan Capital Markets. Mr. Fein began his career at J.P. Morgan H&Q and first gained recognition as a Senior Analyst at Leerink Swann. After that, Mr. Fein worked as a Managing Director/Senior Biotechnology Analyst at Jefferies, Piper Jaffray and Collins Stewart.
Analyst: Kevin Dede
Analyst
Kevin Dede is a Managing Director of Equity Research at H.C. Wainwright. Prior to joining H.C. Wainwright, Mr. Dede conducted over twenty years of institutional research covering different industries such as telecommunications food chain, heavy industry, retail, financial services, and almost all realms of technology. Mr. Dede began his career at Prudential Securities and successively worked for other sell-side investment banks such as Montgomery Securities, Merriman Curhan & Ford, and Auriga LLC.
Analyst: Amit Dayal
Analyst
Amit Dayal is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on small cap growth companies listed in the U.S. Prior to joining H.C. Wainwright, Mr. Dayal was both an advisor for and an investor in tech startups. Mr. Dayal was also a Senior Research Analyst at Rodman & Renshaw for seven years where his research focused on companies operating in emerging markets as well as small and mid-cap companies such as TMT (Technology Media Telecom), Clean Tech, Industrials and Consumer.
Analyst: Dr. Yi Chen, Ph.D.
AnalystDr. Yi Chen is a Managing Director of Equity Research at H.C. Wainwright with expertise in both the biotechnology and the pharmaceutical sectors. Dr. Chen’s research covers investment opportunities in the U.S. healthcare industry. Prior to joining H.C. Wainwright, Dr. Chen worked as an Associate Director of Equity Research at Aegis Capital Corp. and as a Research Associate at Morgan Joseph TriArtisan, LLC. Dr. Chen also worked as a Trading Associate at Zhang Capital Management, a New York-based buy-side fund. Prior to that, Dr. Chen was a Research Associate at the City University of New York where his research focused primarily on protein signaling domains utilizing an RNA interference approach.
Analyst: Dr. Debjit Chattopadhyay
Analyst
Dr. Debjit Chattopadhyay is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on biotechnology, specifically on gene therapy, immune-oncology, and rare diseases. Prior to joining H.C. Wainwright, Dr. Chattopadhyay has been a Wall Street Healthcare Analyst, on the sell-side, working for Janney Montgomery Scott, Roth Capital Partners, and Boenning & Scattergood. Most recently, Dr. Chattopadhyay worked as the Managing Director and the Head of Biotechnology at Janney Montgomery Scott.
Analyst: Vernon T. Bernardino
Analyst
Vernon T. Bernardino is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. Specific therapeutic areas of interest include vascular diseases, gastrointestinal and autoimmune diseases, infectious diseases, metabolic and rare diseases. He possesses over 10 years of experience in the healthcare industry and over 12 years in sell-side and buy-side equity research. Prior to joining H.C. Wainwright, Mr. Bernardino was a healthcare equity research analyst at multiple Wall Street firms including Seaport Global Securities, B. Riley FBR, Rodman & Renshaw LLC, UBS Securities, and Nicholas Applegate Capital Management (now part of Allianz SE). For 2017, Mr. Bernardino was recognized by TipRanks as a Top 150 Wall Street analyst.
Analyst: Ed Arce
Analyst
Ed Arce is a Managing Director of Equity Research at H.C. Wainwright with expertise in both the biopharmaceutical and the specialty pharmaceutical sectors. In particular, Mr. Arce’s research covers investment opportunities among hepatology, renal, infectious disease, gastrointestinal, endocrine, metabolic and select rare disease companies Mr. Arce has been involved in institutionally-focused healthcare research since 2005. Prior to joining H.C. Wainwright, Mr. Arce was a Senior Research Analyst at ROTH Capital Partners. Mr. Arce’s previous sell-side experience includes working for MLV & Co, Wedbush Securities, UBS Securities and First Albany Capital.
H. C. Wainwright & Co.
Analyst
H.C. Wainwright & Co. is one of the country’s oldest financial institutions. H.C. Wainwright & Co. was founded in 1868 at the Union Bank Building in Boston, Massachusetts, located at the heart of the strongest financial center in post-Civil War America. H.C. Wainwright & Co., is a full-service investment bank dedicated to providing corporate fiance, strategic and licensing advisory, research, sales & trading, and related services to pubic and private companies. H.C. Wainwright & Co. has been the leader in the CMPU (confidentially marketed public offerings), RD (registered direct offering) and PIPE (private investment in public equity) transactions since 1998.
